Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 166,250 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $63.99, for a total value of $10,638,337.50. Following the transaction, the chief executive officer owned 8,974,783 shares of the company’s stock, valued at approximately $574,296,364.17. The trade was a 1.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Tempus AI Stock Up 2.3%

Shares of NASDAQ TEM traded up $1.46 during trading hours on Monday, hitting $65.92. The company had a trading volume of 4,162,938 shares, compared to its average volume of 10,597,559. Tempus AI, Inc. has a 1-year low of $31.36 and a 1-year high of $104.32. The stock has a market capitalization of $11.73 billion, a P/E ratio of -55.39 and a beta of 4.99. The firm’s 50 day moving average is $77.83 and its 200-day moving average is $73.81. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The firm had revenue of $334.21 million during the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The business’s revenue for the quarter was up 84.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.46) EPS. On average, analysts expect that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Institutional Trading of Tempus AI

Large investors have recently added to or reduced their stakes in the business. Cranbrook Wealth Management LLC bought a new stake in shares of Tempus AI in the 3rd quarter worth about $25,000. JPL Wealth Management LLC purchased a new position in Tempus AI in the 3rd quarter valued at about $26,000. GAMMA Investing LLC purchased a new stake in Tempus AI in the 3rd quarter valued at $28,000. Concord Wealth Partners raised its stake in shares of Tempus AI by 308.0% in the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after acquiring an additional 308 shares during the period. Finally, Allworth Financial LP raised its stake in shares of Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after acquiring an additional 450 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TEM has been the topic of a number of research reports. Canaccord Genuity Group dropped their target price on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday. Piper Sandler cut their price target on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Guggenheim boosted their price objective on Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, September 26th. Needham & Company LLC raised their target price on Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Finally, JPMorgan Chase & Co. dropped their price target on Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Tempus AI presently has an average rating of “Hold” and an average price target of $84.00.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.